Immobilised biological entities

ABSTRACT

There is described inter alia a medical device having a surface which comprises a coating layer, said coating layer being a biocompatible composition comprising an anti-coagulant entity capable of interacting with mammalian blood to prevent coagulation or thrombus formation, which anti-coagulant entity is covalently attached to said surface through a linker comprising a thioether.

CROSS REFERENCE TO RELATED APPLICATIONS

The present application is a division of U.S. Ser. No. 13/045,769, filedon Mar. 11, 2011 which claims the priority of GB Application Serial No.1004101.0, filed Mar. 12, 2010. The disclosure of the aforementionedapplications are incorporated by reference herein in their entireties,and applicants claim the benefits of these applications under 35 U.S.C.§119.

BACKGROUND OF THE INVENTION

This invention relates to immobilised biological entities, surfaces, andsolid objects, for example medical devices, coated with such entities,and processes and intermediates for their production.

When a medical device is placed in the body, or in contact with bodyfluids, a number of different reactions are set into motion, some ofthem resulting in the coagulation of the blood in contact with thedevice surface. In order to counteract this serious adverse effect, thewell-known anti-coagulant compound heparin has for a long time beenadministered systemically to patients before the medical device isplaced in their body, or when it is in contact with their body fluids,in order to provide an antithrombotic effect.

Thrombin is one of several coagulation factors, all of which worktogether to result in the formation of thrombi at a surface in contactwith the blood. Antithrombin (also known as antithrombin III) (“AT”) isthe most prominent coagulation inhibitor. It neutralizes the action ofthrombin and other coagulation factors and thus restricts or limitsblood coagulation. Heparin dramatically enhances the rate at whichantithrombin inhibits coagulation factors.

However, systemic treatment with high doses of heparin is oftenassociated with serious side-effects of which bleeding is thepredominant. Another rare, but serious complication of heparin therapyis the development of an allergic response called heparin inducedthrombocytopenia that may lead to thrombosis (both venous and arterial).High dose systemic heparin treatment e.g. during surgery also requiresfrequent monitoring of the activated clotting time (used to monitor andguide heparin therapy) and the corresponding dose adjustments asnecessary.

Therefore solutions have been sought where the need for a systemicheparinisation of the patient would be unnecessary or can be limited. Itwas thought that this could be achieved through a surface modificationof the medical devices using the anti-coagulative properties of heparin.Thus a number of more or less successful technologies have beendeveloped where a layer of heparin is attached to the surface of themedical device seeking thereby to render the surface non-thrombogenic.For devices where long term bioactivity is required, heparin shoulddesirably be resistant to leaching and degradation.

Heparin is a polysaccharide carrying negatively charged sulfate andcarboxylic acid groups on the saccharide units. Ionic binding of heparinto polycationic surfaces was thus attempted, but these surfacemodifications suffered from lack of stability resulting in lack offunction, as the heparin leached from the surface.

Thereafter different surface modifications have been prepared whereinthe heparin has been covalently bound to groups on the surface.

One of the most successful processes for rendering a medical devicenon-thrombogenic has been the covalent binding of a heparin fragment toa modified surface of the device. The general method and improvementsthereof are described in European patents: EP-B-0086186, EP-B-0086187,EP-B-0495820 and U.S. Pat. No. 6,461,665.

These patents describe the preparation of surface modified substrates byfirst, a selective cleavage of the heparin polysaccharide chain, e.g.using nitrous acid degradation, leading to the formation of terminalaldehyde groups. Secondly, the introduction of one or more surfacemodifying layers carrying primary amino groups on the surface of themedical device, and thereafter reacting the aldehyde groups on thepolysaccharide chain with the amino groups on the surface modifyinglayers followed by a reduction of the intermediate Schiff's bases toform stable secondary amine bonds.

DE 19604173 relates to medical devices with a polymer surface based on asubstituted bis-phenyl monomer to which a pharmaceutically active agentsuch as heparin may be attached.

WO 2008/090555 relates to a medical device coated with a polymer matrixwhich incorporates a pharmaceutically active agent. It appears that theactive agent may be incorporated within the polymer matrix.

US 2005/0059068 relates to a chemically active surface able tocovalently react with substances containing a hydroxyl group and/or anamine group, comprising a solid surface having an activated dendrimerpolyamine covalently bonded to said surface through a silane containingreagent, wherein the dendrimer polyamine can covalently bind thesubstance comprising a hydroxyl group and/or an amine group.

However there is still a requirement for surface modifications that canbe performed under mild conditions (e.g. which do not degrade theheparin) which are more easily manipulated, are simpler and moreefficient to produce and/or where the bioavailability of the heparinmoiety is higher.

Our earlier application WO 2010/029189 relates to a medical devicehaving a coating with an anticoagulant molecule such as heparincovalently attached to the coating via a 1,2,3-triazole linkage. Thedocument describes the azide or alkyne functionalisation of a polyamine;the preparation of alkyne or azide functionalised heparin (both nativeand nitrous acid degraded heparin); and the reaction to link thederivatised heparin to the derivatised polymer via a 1,2,3-triazolelinker.

We have now found a further simple method of covalently attachingentities capable of interacting with mammalian blood to preventcoagulation or thrombus formation, e.g. heparin, and especially fulllength heparin rather than the degraded heparin of the prior art, to asurface.

SUMMARY OF THE INVENTION

According to the invention we provide, inter alia, a solid object havinga surface which comprises an outer coating layer, said outer coatinglayer being a biocompatible composition comprising a polymer and ananti-coagulant entity capable of interacting with mammalian blood toprevent coagulation or thrombus formation (herein “anti-coagulantentity”), which anti-coagulant entity is covalently attached to saidpolymer through a linker comprising a thioether. Such solid objects,especially medical devices, are thereby non-thrombogenic.

BRIEF DESCRIPTION OF THE FIGURES

FIG. 1: shows photographs of examples of PVC tubing wherein the luminalside is coated and stained with toluidine blue as described in Examples1.1-1.3.

FIG. 2: illustrates the reaction sequence of Example 1.1, in which analkyne functionalized surface reacts with a thiol functionalized heparinto form a thioether linker.

FIG. 3: illustrates the reaction sequence of Example 1.2, in which amaleimide functionalized surface reacts with a thiol functionalizedheparin to form a thioether linker.

FIG. 4: illustrates the reaction sequence of Example 1.3, in which athiol functionalized surface reacts with an alkyne functionalizedheparin to form a thioether linker.

FIG. 5: illustrates the reaction sequence of Example 2a, in whichPolymin SN is functionalized with multiple maleimide groups.

FIG. 6: illustrates the reaction sequence of Example 2b, in whichPolymin SN is functionalized with multiple alkyne groups.

FIG. 7: illustrates the reaction sequence of Example 2c, in whichPolymin SN is functionalized with multiple thiol groups.

DETAILED DESCRIPTION OF THE INVENTION

In general, the outer coating layer comprises a multiplicity ofanti-coagulant entities, each of which is covalently attached to thepolymer through a linker comprising a thioether.

Anti-coagulant entities are well known to those skilled in the art andmany of them are oligosaccharides or polysaccharides. Some of theentities are glycosaminoglycans including compounds containingglucosamine, galactosamine, and/or uronic acid. Among the most suitableglycosaminoglycans are “heparin moieties” and especially full lengthheparin (i.e. native heparin).

The term “heparin moiety” refers to a heparin molecule, a fragment ofthe heparin molecule, or a derivative or analogue of heparin. Heparinderivatives can be any functional or structural variation of heparin.Representative variations include alkali metal or alkaline earth metalsalts of heparin, such as sodium heparin (e.g. Hepsal or Pularin),potassium heparin (e.g. Clarin), lithium heparin, calcium heparin (e.g.Calciparine), magnesium heparin (e.g. Cutheparine), and low molecularweight heparin (prepared by e.g. oxidative depolymerization ordeaminative cleavage, e.g. Ardeparin sodium or Dalteparin). Otherexamples include heparan sulfate, heparinoids, heparin based compoundsand heparin having a hydrophobic counter-ion. Other desirableanti-coagulant entities include synthetic heparin compositions referredto as “fondaparinux” compositions involving antithrombin III-mediatedinhibition of factor Xa. Additional derivatives of heparin includeheparins and heparin moieties modified by means of e.g. periodateoxidation (U.S. Pat. No. 6,653,457) and other modification reactionsknow in the art. Heparin moieties also include such moieties bound to alinker or spacer as described below. De-sulphated heparin is lesssuitable than other forms of heparin because of its reducednon-thrombogenicity relative to other forms of heparin.

Suitably, the anti-coagulant entity is single point attached to thelinker, particularly end point attached. When the anti-coagulant entityis an end point attached heparin moiety, it is suitably connected to thelinker through its reducing end (sometimes referred to herein asposition C1 of the reducing terminal). The advantage of end pointattachment, especially reducing end point attachment, is that thebiological activity of the anti-coagulant entity (for example theheparin moiety) is maximized due to enhanced availability of theantithrombin interaction sites as compared with attachment elsewhere inthe anti-coagulant entity (e.g. heparin moiety).

Where there is a multiplicity of anti-coagulant entities e.g. heparinmoieties it is possible for some or all of them to be of a differenttype; however generally they will all be of the same type.

The term “thioether” refers to a connection between a sulfur and twocarbon atoms. This connection is sometimes referred to as “sulfide”. Thesulphur may be attached to two saturated carbon atoms (i.e. —C—S—C—) orit may be attached to a saturated and an unsaturated carbon atom (i.e.—C—S—C═).

The term “thiol” refers to an —S—H moiety.

The solid object may be any object to which it is desirable to attachanti-coagulant entities. In one embodiment the solid object is a medicaldevice but other solid objects are also contemplated, for exampleanalytical devices and separation devices. Thus, in an alternativeembodiment, the solid object is an analytical device or a separationdevice.

The term “medical device” refers to implantable or non-implantabledevices but more usually to implantable medical devices. Examples ofimplantable medical devices include catheters, stents includingbifurcated stents, balloon expandable stents, self-expanding stents,stent-grafts including bifurcated stent-grafts, artificial bloodvessels, blood indwelling monitoring devices, artificial heart valves,pacemaker electrodes, guidewires, cardiopulmonary bypass circuits,cannulae, balloons, tissue patch devices and blood pumps. Furtherexamples include grafts including vascular grafts and bifurcated grafts,cardiac leads and drug delivery devices. Examples of or non-implantablemedical devices are extracorporeal devices, e.g. extracorporeal bloodtreatment devices, and transfusion devices.

Medical devices may have neurological, peripheral, cardiac, orthopedal,dermal and gynecological application, inter alia.

An analytical device may be, for example, a solid support for carryingout an analytical process such as chromatography or an immunologicalassay, reactive chemistry or catalysis. Examples of such devices includeslides, beads, well plates, membranes etc. A separation device may be,for example, a solid support for carrying out a separation process suchas protein purification, affinity chromatography or ion exchange.Examples of such devices include filters and columns etc.

A medical device may have many coating layers and the term “outercoating layer” refers to a coating layer which, when the device isimplanted in a patient, is in contact with the tissues of the patient oris in contact with body fluids. Thus, the outer coating layer may be thecoating layer on the outer and/or the inner surface of a hollow deviceor a device of open structure such as a stent.

Like a medical device, an analytical device or separation device mayalso have many coating layers and the term “outer coating layer” refersto a coating layer which comes into contact with a substance to beanalysed, separated or handled.

At its simplest the linker consists of the thioether only. However moreusually the linker comprises at least one spacer in addition to thethioether so that the thioether will be separated by a spacer fromeither the polymer or the heparin moiety or both.

The Mw (molecular weight) of the linker is suitably from 10² to 10⁶ Daand the length of the linker is suitably from 10 to 10³ Å. Suitably, thelinkers and/or spacers are straight chain(s), although it is alsopossible for several, i.e. more than one, e.g. from 2 to 100, preferably30 to 100 entities (e.g. heparin moieties) to be attached to a singlelinker thus producing a branched linker in which there are severalheparin moiety side chains.

In some embodiments the linker includes one or more aromatic rings. Inother embodiments the linker does not include any aromatic rings. Insome embodiments the linker is hydrophilic, for example, it may comprisea PEG chain.

In one aspect of the invention, the linker may be formed from multipleportions, for example two, three, four or five portions, more usuallythree, four or five portions, wherein each portion comprises or consistsof a thioether or a spacer.

One example of a three-portion linker comprises “spacer A” between thepolymer and the thioether, the thioether itself and “spacer B” betweenthe thioether and the anti-coagulant entity. The molecular weight ofspacers A and B may be, for example, between about 10¹ and 10³ Da. Inone embodiment, either or both of spacers A and B may comprise anaromatic ring and in an alternative embodiment, neither spacer A norspacer B comprises an aromatic ring.

In this type of linker, either spacer A or spacer B or both may be ahydrophilic spacer, for example a PEG chain.

As used herein, the term “PEG chain” refers to a polymeric chainobtainable by polymerisation of ethylene oxide, typically of weightbetween 10² and 10⁶ Da.

In some cases, the linker may comprise two or more thioethers. Forexample, a bifunctional linker moiety (having, for example an SH groupat each end) can be connected at each end, respectively, to analkyne/alkene functionalized anti-coagulant entity and an alkyne/alkenefunctionalized polymer resulting in the linker containing twothioethers. Alternatively, use of a bis-alkyne/alkene linker can beconnected at each end, respectively, to thiol functionalizedanti-coagulant entity and a thiol functionalized polymer also resultingin the linker containing two thioethers.

Linkers having two or more thioethers suitably comprise three, four orfive portions where, as set out above, each portion comprises athioether or a spacer.

In one embodiment, the linker has five portions—“spacer A” between thepolymer and a first thioether, the first thioether, “spacer C” betweenthe first thioether and a second thioether, the second thioether, and“spacer B” between the second thioether and the anti-coagulant entity.

In such cases, the molecular weights of spacers A and B may be, forexample between about 10¹ and 10³ Da and the molecular weight of spacerC may be between about 10² and 10⁶ Da.

Suitably, one or more of spacer A and/or spacer B and/or spacer C ishydrophilic for example comprising a PEG chain.

In one embodiment, the linker between the anti-coagulant entity such asa heparin moiety and the polymer of the outer coating is an unbranchedlinker. In another embodiment, the linker between the anti-coagulantentity such as a heparin moiety and the polymer of the outer coating isa branched linker wherein the branch contains another anti-coagulantentity such as a heparin moiety.

The linker can be biodegradable or non-biodegradable but is moresuitably non-biodegradable in order that a coated solid object, such asa medical device is non-thrombogenic for a long period of time.

Where there is a multiplicity of linkers it is possible for some or allof them to be of a different type; however suitably all the linkers areof the same type.

In one embodiment, more than one anti-coagulant entity is attached to alinker (e.g. more than one anti-coagulant entity is attached to eachlinker) (see e.g. Example 1.1). In one embodiment more than one linkeris attached to an anti-coagulant entity (e.g. more than one linker isattached to each anti-coagulant entity) (see e.g. Example 1.3).

The surface may comprise a coating layer on a solid object such as amedical device. The solid object may have one or more portionscontaining void spaces, or pores. The pores may be within the solidobject and/or comprising at least one surface of the solid object. Anexample of a porous solid object is expanded polytetrafluoroethylene(ePTFE).

The solid object, may carry one or more, e.g. 2 or more, or 3 or 4 or 5e.g. up to 20 coating layers such that desirably a portion of thesurface (desired to be non-thrombogenic) or the whole of the surface ofthe object is covered (Multilayer Thin Films ISBN: 978-3-527-30440-0).The optimum number of layers will depend on the type of material fromwhich the object is made, and the contemplated use of the surface. Thesurface may, if desired, be made up layer by layer. The number andnature of the layers needed to provide a full coverage of the surfacecan be easily determined by those skilled in the art. The coatinglayer(s) may be formed by adsorbing on the surface of the solid objecthigh average molecular weight cationic polymer, e.g. a polyamine (e.g.that known as Polymin available from BASF, see also EP 0086187 Larssonand Golander) and if needed cross-linking the polyamine with, e.g. analdehyde crosslinker such as crotonaldehyde and/or glutaraldehyde,followed by the application of a solution of an anionic polymer, e.g. ananionic polysaccharide, e.g. dextran sulfate, to obtain at least oneadsorbed layer of the polysaccharide. Hence the surface may comprise alayer of high average molecular weight polyamine and a layer of anionicpolysaccharide. More generally, the surface may comprise one or morecoating bilayers of cationic polymer (e.g. polyamine) and anionicpolymer (e.g. anionic polysaccharide), the innermost layer being a layerof cationic polymer and the outer layer being a layer of cationicpolymer to which the anti-coagulant entity is covalently attached via alinker comprising a thioether. This coating procedure is performedessentially as described in EP-B-0495820. Thus it is only the outercoating layer which comprises the anti-coagulant entity. Typically theouter coating layer to which the anti-coagulant entity is attached isnot cross-linked.

The procedure of EP-B-0495820 may however be modified so that the outerlayer is the anionic polysaccharide which is then reacted, as describedbelow, with a polyamine to which is attached the anti-coagulant entityor a polyamine with functional group(s) capable of forming a linkercomprising a thioether.

Prior to applying the first coating layer the surface of the solidobject, may be cleaned to improve adhesion and surface coverage.Suitable cleaning agents include solvents as ethanol or isopropanol(IPA), solutions with high pH like solutions comprising a mixture of analcohol and an aqueous solution of a hydroxide compound (e.g. sodiumhydroxide), sodium hydroxide solution as such, solutions containingtetramethyl ammonium hydroxide (TMAH), acidic solutions like Piranha (amixture of sulfuric acid and hydrogen peroxide), and other oxidizingagents including combinations of sulfuric acid and potassiumpermanganate or different types of peroxysulfuric acid orperoxydisulfuric acid solutions (also as ammonium, sodium, and potassiumsalts).

Thus an aspect of the invention is a solid object, for example a medicaldevice having a surface wherein the surface comprises one or morecoating bilayers of cationic polymer and anionic polymer, the innermostlayer being a layer of cationic polymer and the outermost layer being anouter coating layer of cationic polymer to which an anti-coagulantentity is covalently attached through a linker comprising a thioether.

The polymer of the outer coating layer is typically a polyamine and theouter coating layer may be formed as described above, either by usingthe procedure described in EP-B-0495820 or a modification of thisprocedure in which an anionic polymer, typically a polysaccharide, isreacted with a polyamine to which is attached the anti-coagulant entityor a functional group capable of forming a linker comprising athioether.

Another aspect of the invention is a non-thrombogenic solid object,especially a non-thrombogenic medical device having a surface comprisinga functionalized cationic polymer outer coating layer whereby ananti-coagulant entity is attached to the cationic polymer outer coatinglayer by means of a linker comprising a thioether.

There are a number of ways of forming a thioether but among the mostsuitable is the reaction of a first compound containing a thiol groupwith a second compound containing an alkene or an alkyne group. Thefirst and second compounds can each be the polymer of which the outercoating layer is comprised and the anti-coagulant entity as appropriate.

Where the second compound is derivatised with an alkene, in oneembodiment an activated alkene is used. An example of a suitableactivated alkene is a maleimide derivative.

As noted below, optionally reaction may take place in the presence of areducing agent such as tris(2-carboxyethyl)phosphine hydrochloride, oralternatively dithiothreitol or sodium borohydride, to avoid or reversethe effective of undesirable coupling of two thiol groups throughoxidation.

In one embodiment the reaction is initiated with a radical initiator. Anexample of a radical initiator is 4,4′-azobis(4-cyanovaleric acid).Further examples are potassium persulfate,2,2′-azobis[2-(2-imidazolin-2-yl)propane]dihydrochloride and4-(trimethyl ammoniummethyl) benzophenone chloride.

In another embodiment, the reaction is not initiated with a radicalinitiator. Instead, conditions of higher pH (e.g. pH 8-11) are used.This type of reaction is more suitable when an activated alkene oralkyne is used for reaction with the thiol.

In general, however, it is preferable to employ acid conditions becausethese conditions appear most compatible with the heparin and the coatingmaterials.

The reaction between a first compound containing a thiol group and asecond compound containing an alkyne group may be represented asfollows:

where one of R^(a) and R^(b) is the polymer and the other of R^(a) andR^(b) is the anti-coagulant entity.

The reaction is described in Example 1.1, where R^(a) is heparin andR^(b) is a polyamine and in Example 1.3, where R^(a) is polyamine andR^(b) is heparin. The reaction may, for example, be carried out in thepresence of tris(2-carboxyethyl)phosphine hydrochloride as reducingagent, and 4,4′-Azobis(4-cyanovaleric acid) as radical initiator, andunder acidic conditions.

If an excess of the compound R^(a)—SH is present, there may be furtheraddition across the alkene double bond to produce a compound containingtwo R^(a) groups linked to a single R^(b) group. Again this isillustrated in Example 1.1, where some of the linkers have more than oneheparin group attached and in Example 1.3, where some of the heparin isattached to several linkers.

The reaction between a first compound containing a thiol group and asecond compound containing a maleimide group may be represented asfollows:

where one of R^(a) and R^(b) is the polymer and the other of R^(a) andR^(b) is the anti-coagulant entity.

This is described in detail in Example 1.2, where R^(a) is heparin andR^(b) is a polyamine. The reaction is generally carried out in thepresence of tris(2-carboxyethyl)phosphine hydrochloride as reducingagent, and 4,4′-azobis(4-cyanovaleric acid) as radical initiator, andunder acidic conditions.

Another aspect of the invention is a process for preparing anon-thrombogenic solid object, for example a non-thrombogenic medicaldevice, the process comprising:

-   -   (a) treating a solid object such as a medical device to present        a surface comprising a cationic polymer outer coating layer        which has been functionalized to bear thiol groups;    -   (b) reacting said cationic polymer outer coating layer which has        been functionalized to bear thiol groups with an anti-coagulant        entity which is functionalized to bear an alkene or alkyne        group;    -   thereby to attach the anti-coagulant entity to the cationic        polymer through a linker comprising a thioether.

The invention also provides a solid object, particularly a medicaldevice obtainable by this process.

Another aspect of the invention is a process for preparing anon-thrombogenic solid object, for example a non-thrombogenic medicaldevice, the process comprising:

-   -   (a) treating a solid object such as a medical device to present        a cationic polymer outer coating layer which has been        functionalized to bear alkene or alkyne groups;    -   (b) reacting said cationic polymer outer coating layer which has        been functionalized to bear alkyne groups with an anti-coagulant        entity which is functionalized to bear a thiol group;    -   thereby to attach the anti-coagulant entity to the cationic        polymer through a linker comprising a thioether.

The invention also provides a solid object, particularly a medicaldevice obtainable by this process.

Another aspect of the invention is a process for preparing anon-thrombogenic solid object, for example a non-thrombogenic medicaldevice, the process comprising:

-   -   (a) treating a solid object such as a medical device to present        a cationic polymer surface layer;    -   (b) associating with said cationic polymer surface layer a        functionalized cationic polymer bearing a multiplicity of        negatively charged anti-coagulant entities such as heparin        moieties which are attached thereto via a linker comprising a        thioether said cationic polymer bearing a multiplicity of        negatively charged anti-coagulant entities and said        functionalized cationic polymer having a net negative charge.

The invention also provides a solid object, particularly a medicaldevice obtainable by this process.

As described above, the cationic polymer surface may be prepared bytreating the solid object with a high average molecule weight cationicpolymer such as a polyamine and if necessary cross-linking it with e.g.an aldehyde cross-linker. Further layers may optionally be built up bysuccessive steps of (i) application of a solution of anionic polymer(e.g. anionic polysaccharide) to obtain an adsorbed layer of the anionicpolymer and (ii) then further treating that with functionalized cationicpolymer, such as a polyamine, to provide an adsorbed outer coating layerof functionalized cationic polymer, the outer coating layer beingfunctionalized to bear thiol groups or alkene or alkyne groups.

Typically the first step of treating the object with a high averagemolecule weight cationic polymer is preceded by the step of cleaning thesurface of the object with suitable cleaning agents (e.g. thosementioned above) or other methods of surface pretreatment known in theart to improve adherence and coverage of the first layer e.g. thepolyamine layer.

Another aspect of the invention is a process for preparing anon-thrombogenic solid object, for example a non-thrombogenic medicaldevice, the process comprising:

-   -   (a) treating a solid object such as a medical device to present        an anionic polymer surface layer;    -   (b) associating with said anionic polymer surface layer a        functionalized cationic polymer bearing a multiplicity of        negatively charged anti-coagulant entities such as heparin        moieties which are attached thereto via a linker comprising a        thioether, said functionalized cationic polymer bearing a        multiplicity of negatively charged anti-coagulant entities and        having a net positive charge.

The invention also provides a solid object, particularly a medicaldevice obtainable by this process.

As described above, the solid object which presents an anionic polymersurface layer is typically prepared by treating the object (e.g. medicaldevice) with a high average molecule weight cationic polymer, such as apolyamine, optionally with cross-linking, followed by treating thepolyamine surface with a solution of anionic polymer (e.g. anionicpolysaccharide) to obtain an adsorbed outer layer of the anionicpolymer. Further layers may be built up by successive steps of (i)application of a cationic polymer (optionally with cross-linking) toprovide an adsorbed layer of cationic polymer and (ii) then treatingthat with a solution of anionic polymer (e.g. anionic polysaccharide) toobtain an adsorbed outer layer of the anionic polymer.

Suitably the anionic polymer is a polysaccharide such as dextran sulfateor a derivative thereof.

As used herein a “polyamine” is a molecule having multiple (e.g. 10,100, 1000 or more) free pendant amino groups preferably containing atleast some primary amino groups. Polyamines are typically polymericmolecules having multiple amino groups of high average molecular weight,for example having an average molecular weight of 10³-10⁶ Da. Anexemplary polyamine is a polyethyleneimine such as that known as Polyminavailable from BASF.

The cationic polymer may be functionalized using techniques known in theart. As illustrated in the Examples below, primary amino groups on thepolyamine may be used as points of attachment for the alkene, alkyne orthiol group. However a skilled person would know how to adapt thechemistry to use secondary amino groups on the polyamine as points ofattachment for the alkene, alkyne or thiol group. Hence polyamines maybe functionalized to bear alkene, alkyne or thiol groups by conventionalmeans e.g. by reacting pendant primary amino groups on the polyaminewith an activated carboxylic acid (e.g. an N-hydroxy succinimidederivative of a carboxylic acid) which acid bears an alkene, alkyne orthiol group. Another way is to react secondary amines with carboxylicacids with carbodiimide chemistry or to react with carboxylic acidchlorides where the carboxylic acid portion bears an alkene, alkyne orthiol group.

The anti-coagulant entity, e.g. heparin, carrying an alkene, alkyne orthiol group may be made by conventional methods known per se. Forexample an anti-coagulant entity, e.g. heparin, carrying analkyne/alkene group may be made by the reaction of an alkoxyamine of theformula:R¹—O—NH₂

wherein R¹ is an alkyne/alkene-containing group;

with an aldehyde or hemi-acetal group on the anti-coagulant entity usingconventional techniques known per se. This type of reaction isillustrated below in Example 3b; the reaction proceeds via formation ofan oxy-imine function to give a compound of the formula:R¹—O—N═R′

in which R¹ is as defined above and R′ is the residue of theanti-coagulant entity.

Nitrous acid degraded heparin and native heparin bear reactive groups,an aldehyde group and a hemi-acetal function respectively, at theirreducing end which may be linked in this way.

Similarly, an anti-coagulant entity derivatised with a thiol group maybe formed by the reaction of an aldehyde or hemi-acetal group on theanti-coagulant entity with a compound of the formula:HS—X—NH₂

where X is a hydrocarbon linker, for example (CH₂)_(n) where n is 1 to 8e.g. 1 to 4, or X is a hydrocarbon linker as just described in which oneor more (e.g. 1 or 2) methylene groups are replaced by O; or X comprisesa PEG chain containing 1 to 100 (e.g. 1 to 50 such as 1 to 10) ethyleneglycol units;

to give a product of the formulaR′—CH₂—NH—X—SH

where X is as defined above and R′—CH₂— is the residue of theanti-coagulant entity.

An example of such a procedure is given in Example 3a below.

A suitable functional group must also be introduced into the polymer ofthe outer coating layer so that it can be reacted with the derivatisedanti-coagulant entity.

For example, a polyamine polymer bearing a number of primary aminegroups represented as follows:R″—NH₂

where R″ is the polymer residue;

may be reacted with a compound of the formula:

where n is an integer from 1 to 8 e.g. 1 to 4;

to give a maleimide functionalized polyamine of the formula:

where R″ and n are as defined above. This reaction is illustrated inmore detail in Example 2a below.

Alternatively, the polyamine polymer may be reacted with an activatedalkyne-containing group of the formula:

where n is an integer from 1 to 8 e.g. 1 to 4;

to give an alkyne functionalized polymer of the formula:

where R″ and n are as defined above. This reaction is illustrated inmore detail in Example 2b below.

Alternatively, if the polymer is intended to be reacted with an alkeneor alkyne-derivatised anti-coagulant entity, it may be derivatised witha thiol group. In this case, a polyamine polymer bearing a number ofprimary amine groups represented as follows:R″—NH₂

where R″ is as defined above;

may be reacted with an activated thiol-containing compound, for examplea compound of the formula:

where n is an integer from 1 to 8 e.g. 1 to 4;

to give a derivatised polymer of the formula:

where R″ and n are as defined above. This reaction is illustrated inmore detail in Example 2c below.

When a coating layer is used, the surface of all and any solid objectsis transformed to present the same functionalized outer surface for thesubsequent attachment of an anti-coagulant entity capable of interactingwith mammalian blood to prevent coagulation or thrombus formation. Hencea specific advantage of the processes described herein is that generallya very uniform non-thrombogenic surface is created (see the Figure).This is particularly useful when the solid object is a medical device.

The solid object, e.g. medical device may comprise a metal or asynthetic or naturally occurring organic or inorganic polymer.

Thus, for example, it may be formed from a synthetic or naturallyoccurring organic or inorganic polymer or material such as polyethylene,polypropylene, polyacrylate, polycarbonate, polyamide, polyurethane(PU), polyvinylchloride (PVC), polyetherketone (PEEK), cellulose,silicone or rubber (polyisoprene), plastics materials, metals, glass,ceramics and other known medical materials or a combination of suchmaterials. Other suitable substrate materials include fluoropolymers,e.g expanded polytetrafluoroethylene (ePTFE), polytetrafluoroethylene(PTFE), fluorinated ethylene-propylene (FEP), perfluorocarboncopolymers, e.g. tetrafluoroethylene perfluoroalkylvinyl ether(TFE/PAVE) copolymers, copolymers of tetrafluoroethylene (TFE) andperfluoromethyl vinyl ether (PMVE), and combinations of the above withand without crosslinking between the polymer chains.

Suitable metals include nickel titanium alloy (Nitinol), stainlesssteel, titanium, cobalt chromium, gold and platinum. Nitinol andstainless steel are preferred. Titanium is also preferred.

A particularly suitable embodiment of the present invention relates to acoated medical device.

A medical device can be implantable or non-implantable. Examples ofimplantable or non-implantable medical devices include catheters,stents, stent-grafts, artificial blood vessels, blood indwellingmonitoring devices, artificial heart valves, pacemaker electrodes,guidewires, cardiopulmonary bypass circuits, cannulae, balloons, tissuepatch devices, blood pumps, and extracorporeal devices, e.g.extracorporeal blood treatment devices, and transfusion devices.

We prefer the coated surface to which the anti-coagulant entity (e.g.heparin or other heparin moiety) is attached to be such that it retainsnon-thrombogenic properties after sterilization, e.g. ethylene oxide(EO) sterilization.

Sterilization may be carried out by means well known to those skilled inthe art. The preferred method of sterilization is using ethylene oxidegas. Alternatively, other methods such as radiation, e.g. e-beam orgamma radiation, may be used where such radiation will not degrade theobject or the coating or both.

A preferred embodiment of the present invention relates to a coatedmedical device for implantation e.g. permanent implantation, or otherplacement, at an anatomical site. Other preferred embodiments includetemporary use devices such as catheters and extracorporeal circuits.Examples are sterile (e.g. sterilized) medical devices for placementinside an anatomical structure delimiting a void space, or lumen, toreinforce the anatomical structure or maintain the void space. Suitablythe attached anti-coagulant entity, e.g. heparin or other heparinmoiety, does not elute to any substantial extent and remains with thedevice. For example, after 15 hour rinse with NaCl (0.15 M) prior totesting the retained AT binding activity remains adequate (e.g. greaterthan 1 or 2 or 4 or 5 or 10 pmol/cm²) and when tested in the Blood loopevaluation test (see Example 1.4) with fresh blood from a healthy donorthe reduction in platelet count of the blood after the test issubstantially lower for the blood exposed to the coated surfaceaccording to the invention than that of an uncoated control (e.g. thereduction in platelet count after the test for the blood exposed to thecoated surface is less than 20%, preferably less than 15% and morepreferably less than 10%).

Suitably the biocompatible composition of the invention is notbiodegradable or bioabsorbable. For biodegradable or bioabsorbablecompositions the non-thrombogenic properties may generally be expectedto be limited in time.

The non-thrombogenic character of solid objects according to the presentinvention may be tested by a number of methods. For examplenon-thrombogenic character may be associated with having a highantithrombin binding activity, especially as compared with solid objectshaving untreated surfaces.

For example, we prefer the surface, e.g. of the medical device, to havean antithrombin (AT) binding activity of at least 1 e.g. at least 5picomoles AT per square centimeter (pmol/cm²) of surface. In otherembodiments, the AT binding activity is at least 6 pmol/cm², at least 7pmol/cm², at least 8 pmol/cm², at least 9 pmol/cm², or at least 10pmol/cm² of surface. In some embodiments, the AT binding activity is atleast 100 pmol/cm² of surface. AT binding activity can be measured bymethods known in the art, e.g. those described in Pasche., et al., in“Binding of antithrombin to immobilized heparin under varying flowconditions” Artif.-Organs 15:481-491 (1991) and US 2007/0264308. By wayof comparison it may be concluded from Sanchez et al (1997) J. Biomed.Mater. Res. 37(1) 37-42, see FIG. 1, that AT binding values of around2.7-4.8 pmol/cm² (depending on the experimental set up) or more do notappear to give rise to significant thrombogenic enzymatic activity uponcontact with plasma.

Alternatively or additionally we prefer the surface to benon-thrombogenic due to high capacity to suppress coagulation and otherdefence systems in the Blood loop evaluation test described in Example1.4. According to that test, the surface to be investigated is appliedto a PVC tubing which is rinsed for 15 hours with 0.15M NaCl prior totesting with fresh blood. Non-thrombogenicity is indicated by areduction in platelet count of the blood measured after the test whichis substantially lower for the blood exposed to the surface preparedaccording the method described herein than that of an uncoated control(e.g. the reduction in platelet count after the test for the bloodexposed to the coated surface is less than 20%, preferably less than 15%and more preferably less than 10%).

Other similar blood evaluation methods different from the Blood loopmodel can be performed by those skilled in the art in order to assessthrombogenicity/non-thrombogenicity.

The amount of the anti-coagulant entity bound to a particular surfacearea can be controlled and adjusted, e.g. by adjusting the amount of thereagents used in the synthesis of the composition.

The distribution of the anti-coagulant entity on the surface can bedetermined by conventional staining techniques which are known per se,e.g. the distribution of heparin can be determined using toluidine blue.

According to the invention we also provide a process for the productionof a solid object, in particular a medical device, having a surfacewhich comprises an outer coating layer, said outer coating layer being abiocompatible composition comprising a polymer and an anti-coagulantentity capable of interacting with mammalian blood to preventcoagulation or thrombus formation, which anti-coagulant entity iscovalently attached to said polymer through a linker comprising athioether which process comprises the reaction of a correspondinganti-coagulant entity carrying an alkene or alkyne group with acorresponding surface carrying a thiol group, or the reaction of acorresponding anti-coagulant entity carrying a thiol group with acorresponding surface carrying an alkene or alkyne group.

This process may be carried out using procedures known per se.

The surface carrying a thiol group or an alkene or alkyne group may bemade by conventional methods known per se, e.g. by reacting a surface,e.g. a surface as described in EP-B-0086186 or EP-B-0086187 carryingnegatively charged sulfate groups with an appropriate polyamine carryingeither a thiol or an alkene or alkyne group respectively.

According to the invention we also provide a polyamine carrying ananti-coagulant entity through a linker comprising a thioether.

In one embodiment in which the reaction is used the surface carries thethiol group. In another embodiment in which the reaction is used theanti-coagulant entity carries the thiol group.

The reaction may be carried out as described briefly above and in moredetail in the Examples below.

By this new method the anti-coagulant entity, e.g. heparin, canadvantageously be bound to the surface by surface groups that are notinvolved in the build up of the surface covering. By contrast, the priorart described in EP-B-0086186, EP-B-0086187 and EP-B-0495820 uses thesame type of groups (primary amines) in the layer by layer surfacecoating process as those used to bind the heparin to the coating.

This new process tends to be less sensitive to pH than are the prior artprocesses which is also advantageous.

The reaction may also, if desired, be carried out under flow conditions.

According to the invention we also provide an anti-coagulant entity,e.g. heparin or other heparin moiety, which anti-coagulant entitycarries an alkene or alkyne or a thiol group. We also provide ananti-coagulant entity, e.g. a heparin moiety capable of interacting withmammalian blood to prevent coagulation or thrombus formation, whereinthe anti-coagulant entity carries an alkene or alkyne or a thiol group,which alkene or alkyne or thiol group is attached to a linker, whereinthe linker is end-point attached to the anti-coagulant entity (e.g.heparin moiety). When the anti-coagulant entity is a heparin moiety, itmay, for example. be a full length heparin moiety (i.e. native heparin).

According to the invention we also provide a functionalized polyaminesurface, e.g. a surface prepared essentially as described inEP-B-0086186, EP-B-0086187 and, EP-B-0495820, but additionally carryingone or more thiol or one or more alkene or alkyne groups on the outercoating layer of polyamine.

According to the invention we also provide a solid object, especially amedical device, having a polyamine surface carrying a thiol or an alkeneor alkyne group e.g. a thiol or alkene or alkyne group which isconnected to an amino group of the polyamine surface via a linker.

According to a further feature of the invention we also provide aprocess for the production of a solid object, especially a medicaldevice, having a surface which comprises an outer coating layer, saidouter coating layer being a biocompatible composition comprising apolymer and an anti-coagulant entity capable of interacting withmammalian blood to prevent coagulation or thrombus formation, whichanti-coagulant entity is covalently attached to said polymer through alinker comprising a thioether, wherein the object has a surface whichcomprises one or more layers of polysaccharide and polyamine, whichprocess comprises the reaction of a corresponding surface having anouter layer of polysaccharide which has a net negative charge (i.e.anionic polysaccharide e.g. carrying negatively charged sulfate groups)with a polyamine, carrying a corresponding anti-coagulant entity througha linker comprising a thioether, having a net positive charge, or thereaction of a corresponding surface having an outer layer ofpolysaccharide which has a net negative charge (i.e. anionicpolysaccharide e.g. carrying negatively charged sulfate groups) with apolyamine carrying a thiol or an alkene or alkyne group which has a netpositive charge and reacting the resulting product with ananti-coagulant entity carrying an alkene or alkyne or a thiol grouprespectively.

References to a polyamine carrying an anti-coagulant entity or a thiol,alkene or alkyne groups include references to a polyamine carrying oneor more i.e. a plurality of such groups. However a polyamine carrying acorresponding anti-coagulant entity through a linker comprising athioether having a net positive charge will only bear so many negativelycharged anti-coagulant entities as allows the net charge to remain netpositive.

According to a further feature of the invention we also provide aprocess for the production of a solid object, e.g. a medical device,having a surface which comprises an outer coating layer, said outercoating layer being a biocompatible composition comprising a polymer andan anti-coagulant entity capable of interacting with mammalian blood toprevent coagulation or thrombus formation, which anti-coagulant entityis covalently attached to said polymer through a linker comprising athioether, wherein the object has a surface which comprises one or morelayers of polysaccharide (i.e. anionic polysaccharide e.g. carryingnegatively charged sulfate groups) and polyamine, which processcomprises the reaction of a corresponding surface having an outer layerof polyamine having a net positive charge with a polyamine carrying amultiplicity of corresponding anti-coagulant entities through a linkercomprising a thioether such that said polyamine has a net negativecharge.

This process for putting down the layers of polysaccharide and polyaminemay be carried out using procedures known per se, for example proceduresanalogous to those described in EP-B-0495820.

The presence of a net positive charge on a surface may be determined bytreatment with Ponceau S which would dye a positively charged surface ared colour.

The presence of a net negative charge on a surface may be determined bytreatment with toluidine blue which would dye a negatively chargedsurface a blue colour.

According to the invention we also provide a functionalized polyamine,e.g. Polymin which carries one or more thiols or one or more alkenes orone or more alkynes e.g. via a linker.

According to the invention we also provide a functionalized polyaminecarrying an anti-coagulant entity attached thereto through a linkercomprising a thioether. This polyamine may be made by procedures knownper se, e.g. analogous to those described elsewhere in thisspecification.

The products of the invention may have one or more of the followingadvantageous properties:

-   -   The degree of substitution of the anti-coagulant entity on the        surface can be controlled;    -   Both end-point (single point) attachment and multi-point        attachment of the anti-coagulant entity, e.g. heparin, can be        achieved, although end point (especially reducing end point)        attachment is preferred;    -   The linker length between the anti-coagulant entity and the        surface can be controlled;    -   Full length heparin can be used thus avoiding the cleavage of        heparin and the waste of parts of the cleaved product involved        in the prior art nitrous acid degradation of heparin;    -   When cleaving heparin, the antithrombin binding sequence can be        destroyed in some of the fragments, therefore using full-length        heparin or heparin linked via a spacer can also improve the        bioavailability of the bound heparin;    -   A uniform distribution of the anti-coagulant entity over the        surface can be obtained;    -   A uniform coating may be obtained which will mask the intrinsic        properties, for example lower the thromogenic properties, of a        device irrespective of the material of its manufacture;    -   A coating may be obtained which is comparatively smooth;    -   The biocompatibility of the coating may be enhanced;    -   A coating according to the present invention may reduce the need        for systemic heparin and reduce the likelihood of contact        activation;    -   The bioavailability of the anti-coagulant entity can be        controlled, e.g. by the use of different linkers (length, type);    -   A non-thrombogenic surface which does not leach heparin and        therefore has long lifetime can be obtained;    -   An analytical or separation device with improved binding        capacity to biomolecules may be obtained; and    -   An analytical or separation device with extended heparin        activity life time may be obtained.

Other aspects of the invention include a biocompatible compositioncomprising an anti-coagulant entity capable of interacting withmammalian blood to prevent coagulation or thrombus formation whichanti-coagulant entity is covalently attached to a surface through alinker comprising a thioether.

The skilled person will appreciate that the biocompatible compositionmay be applied to any solid object, of which a medical device is justone example. Therefore according to another aspect of the inventionthere is provided a solid object having a surface comprising (e.g.coated with) such a biocompatible composition.

The invention is illustrated, but in no way limited, by the followingExamples:

EXAMPLE 1.1 Preparation of a Non-Thrombogenic Surface on PVC

A surface comprising layers of aminated polymer and sulfatedpolysaccharide having a functionalized aminated polymer outer layer isconnected to functionalized heparin thereby forming a thioether.

A PVC surface was pretreated using the method described by Larm et al inEP-B-0086186 and EP-495820 (layer-by-layer; polyelectrolyte chargeinteractions) ending with a layer of sulfated polysaccharide.

The luminal surface of a PVC tubing (I.D. 3 mm) was cleaned withisopropanol and an oxidizing agent. The priming was built-up byalternated adsorption of a positively charged polyamine (Polymin) andnegatively charged sulfated polysaccharide (dextran sulfate). Thepolyamine is crosslinked with a difunctional aldehyde (crotonaldehyde).Every pair of polyamine and sulfated polysaccharide is called onebilayer. The PVC surface was primed with 4 bilayers ending with thesulfated polysaccharide.

Polymin SN (Lupasol SN; Lupasol is an alternative trade name forPolymin) was diluted with water to prepare a stock solution (5 g PolyminSN was added to 20 mL purified water). (Polymin is a polyethyleneiminecationic tenside available from BASF).

1.0 mL of a 5% solution of alkyne functionalized polyamine (preparationsee Example 2b) was added to 500 mL of a 0.04 M/0.04 M borate/phosphatebuffer at pH 8.0. The adsorption of the alkyne functional polyamine tothe sulfate surface was carried out for 20 minutes at room temperature.A two minute water rinse was performed after the adsorption to rinse offexcess polymer.

500 mg of nitrite degraded heparin, with thiol functionalization at C1of the reducing terminal (prepared as in Example 3a), was dissolved in1000 mL of de-ionized water and 50 mg tris(2-carboxyethyl)phosphinehydrochloride, 500 mg 4,4′-Azobis(4-cyanovaleric acid), and 2.9 g NaClwere added. The pH was adjusted to 3.7 with 1 M HCl (aq).

The reaction between the solution of the thiol functionalized heparinand the alkyne functionalized surface was carried out at 70° C. for 3 h.Purification was performed by rinsing off non-covalently linked heparinfor 10 minutes using a 0.04 M/0.04 M borate/phosphate buffer at pH 8.0.A final rinse with de-ionized water for two minutes was performed towash away buffer salt residues.

The flow used during the entire process was 100 mL/min.

The samples were stained with toluidine blue (“TB”) (200 mg/L in water)by immersing in the solution for 2 minutes followed by extensive waterrinse. The TB attaches to the heparin via ionic interaction. The samplesshowed intense uniform stain with TB, see the Figure.

Antithrombin binding activity of bound heparin: 2.2 pmol/cm²

The antithrombin binding activity of bound heparin was measuredessentially as described in Pasche., et al., in “Binding of antithrombinto immobilized heparin under varying flow conditions” Artif.-Organs15:481-491 (1991).

Non-thrombogenic as tested by the blood loop—see Example 1.4

EXAMPLE 1.2 Preparation of a Non-Thrombogenic Surface on PVC

The luminal surface of a PVC tubing (internal diameter 3 mm) was cleanedwith isopropanol and an oxidizing agent. It was then primed with fourbilayers of a positively charged polyamine (Polymin) and a negativelycharged sulfated polysaccharide (dextran sulfate) ending with thesulfated polysaccharide.

Then next coating step used a solution of 10 mL of a 1% solution ofmaleimide functionalized polyamine (prepared as in Example 2a) in 1000mL of a 0.04 M/0.04 M borate/phosphate buffer at pH 8.0. The adsorptionof the maleimide functional polyamine to the sulfate surface was carriedout for 20 minutes at room temperature. A two minute water rinse wasperformed after the adsorption to rinse off excess polymer.

500 mg of nitrite degraded heparin, with thiol functionalization at C1of the reducing terminal (prepared as in Example 3a), was dissolved in1000 mL of de-ionized water and 50 mg tris(2-carboxyethyl)phosphinehydrochloride, 500 mg 4,4′-Azobis(4-cyanovaleric acid), and 2.9 g NaClwere added. The pH was adjusted to 3.7 with 1 M HCl (aq).

The reaction between the solution of the thiol functionalized heparinand the maleimide functionalized surface was carried out at 70° C. for 3h. Purification was performed by rinsing off non-covalently linkedheparin for 10 minutes using a 0.04 M/0.04 M borate/phosphate buffer atpH 8.0. A final rinse with de-ionized water for two minutes wasperformed to wash away buffer salt residues.

The flow used during the entire process was 100 mL/min.

Staining with TB (as described in Example 1.1) showed an intense uniformstain after coating, see the Figure.

Antithrombin binding activity of bound heparin: 8.0 pmol/cm²

Non-thrombogenic as tested by the blood loop—see Example 1.4

EXAMPLE 1.3 Preparation of a Non-Thrombogenic Surface on PVC

The luminal surface of a PVC tubing (internal diameter 3 mm) was cleanedwith isopropanol and an oxidizing agent. It was then primed with fourbilayers of a positively charged polyamine (Polymin) and a negativelycharged sulfated polysaccharide (dextran sulfate) ending with thesulfated polysaccharide.

Then next coating step used a solution of 5 mL of a 1% solution of thiolfunctionalized polyamine (prepared as in Example 2c) and 125 mg oftris(2-carboxyethyl)phosphine hydrochloride in 500 mL of a 0.04 M/0.04 Mborate/phosphate buffer at pH 8.0. The adsorption of the thiolfunctional polyamine to the sulfate surface was carried out for 20minutes at room temperature. A two minute water rinse was performedafter the adsorption to rinse off excess polymer.

250 mg of nitrite degraded heparin, with alkyne functionalization at C1of the reducing terminal (prepared as in Example 3b), was dissolved in500 mL of de-ionized water and 25 mg tris(2-carboxyethyl)phosphinehydrochloride, 250 mg 4,4′-Azobis(4-cyanovaleric acid), and 1.4 g NaClwere added. The pH was adjusted to 3.7 with 1 M HCl (aq).

The reaction between the solution of the alkyne functionalized heparinand the thiol functionalized surface was carried out at 70° C. for 3 h.Purification was performed by rinsing off non-covalently linked heparinfor 10 minutes using a 0.04 M/0.04 M borate/phosphate buffer at pH 8.0.A final rinse with de-ionized water for two minutes was performed towash away buffer salt residues.

The flow used during the entire process was 100 mL/min.

Staining with TB (as described in Example 1.1) showed an intense uniformstain after coating, see the Figure.

Antithrombin binding activity of bound heparin: 1.0 pmol/cm²

Non-thrombogenic as tested by the blood loop—see Example 1.4

EXAMPLE 1.4 Blood Loop Evaluation Test

Blood loop evaluation was performed on the luminaly coated PVC tubesamples from Examples 1.1-1.3 to show the preserved heparin bioactivityof the non-thrombogenic surface. First the luminal side of the coatedtubings were washed with 0.15 M NaCl for 15 hours at a flow of 1 mL/minto ensure that all loosely bound heparin was rinsed off and a stablesurface remains. Then the washed tubings were incubated in a Chandlerloop model performed essentially according to Anderson et al.(Andersson, J.; Sanchez, J.; Ekdahl, K. N.; Elgue, G.; Nilsson, B.;Larsson, R. J Biomed Mater Res A 2003, 67(2), 458-466) at 20 rpm. Theplatelets, from fresh blood and from the blood collected from the loops,were counted in a cell counter to measure the loss of platelets whichindicates thrombosis. As references were included a non-thrombogeniccontrol (i.e Carmeda® BioActive Surface applied to PVC, which isprepared essentially as described in EP-B-0495820), an uncoated PVCtube, and a thrombogenic control (i.e. a three bilayer coating with anouter layer of sulfated polysaccharide not binding antithrombin).

As seen in the table below, there is virtually no platelet loss(platelet loss indicates thrombosis) seen for the coatings prepared asdescribed in Examples 1.1-1.3. The uncoated PVC tubing and the surfacewith an outer layer of sulfated polysaccharides (not bindingantithrombin) show significant platelet loss in this experiment.

Loss in Platelet count × platelet Evaluated surfaces 10⁹/L count %Initial value, blood 202 before Chandler loop Evaluated surfaces FromExample 1.1 206 0 according to the From Example 1.2 190 6 invention FromExample 1.3 199 1 Reference surfaces Non-thrombogenic 194 4 controlUncoated PVC tube 57 72 Thrombogenic 9 96 control

These results demonstrate the non-thrombogenic properties of the surfaceprepared according to the invention.

Example 2a Maleimide Functionalization of Polymin SN

Polymin SN (Lupasol SN; Lupasol is an alternative trade name forPolymin) was diluted with water to prepare a stock solution (5 g PolyminSN was added to 20 mL purified water). (Polymin is a polyethyleneiminecationic tenside available from BASF).

4-maleimidobutyric acid (0.50 g, 2.7 mmol) and N-hydroxysuccinimide(NHS) (0.32 g, 2.7 mmol) was dissolved in 3 mL of dichloromethane andstirred at 0° C. A solution of N,N′-dicyclohexylcarbodiimide (0.56 g,2.7 mmol) in 3 mL of dichloromethane was added slowly to the reactionmixture at 0° C. The reaction mixture was stirred over night and thebyproducts were filtered of and the NHS activated 4-maleimidobutyricacid was concentrated and dried under vacuum.

The dried NHS activated 4-maleimidobutyric acid was dissolved in 30 mLof purified water and mixed with 7.6 mL of the Polymin SN stock solutionat 0° C. and left to react overnight at room temperature to obtain a 1%solution of the maleimide functionalized polymin.

EXAMPLE 2b Alkyne Functionalization of Polymin SN

A solution of N-hydroxysuccinimide-(4-pentynoate) (Ref: Salmain, M.;Vessieres, A.; Butler, I. S.; Jaouen, G. Bioconjugate Chemistry 1991,2(1), 13-15) (3.90 g, 19.0 mmol) in 20 mL of purified water was mixedwith 24 mL of the Polymin SN stock solution (see example 2a) and left toreact overnight at 70° C. The reaction mixture was then diluted withwater and isopropanol (min 99%, PhEur quality, Merck) until the polymerprecipitated. The isopropanol was decanted off and the residualisopropanol of the resulting slurry was evaporated off.

EXAMPLE 2c Thiol Functionalization of Polymin SN

3-mercaptopropionic acid (1.00 g, 9.4 mmol) and N-hydroxysuccinimide(NHS) (1.09 g, 9.4 mmol) was dissolved in 1 mL of dichloromethane andstirred at 0° C. under inert atmosphere (Ar).

A solution of N,N′-dicyclohexylcarbodiimide (1.94 g, 9.4 mmol) in 10 mLof dichloromethane was added slowly to the reaction mixture at 0° C. Thereaction mixture was stirred over night under inert atmosphere (Ar) atroom temperature and the byproducts were filtered of and the NHSactivated 3-mercaptopropionic acid was concentrated and dried undervacuum.

The dried NHS activated 3-mercaptopropionic acid was dissolved in 115 mLof purified water and mixed with 28.6 mL of the Polymin SN stocksolution (see example 2a) at 0° C. and left to react overnight underinert atmosphere (Ar) at room temperature to obtain a 1% solution of thethiol functionalized polymin.

EXAMPLE 3a Preparation of Thiol Functionalized Nitrous Acid DegradedHeparin

Nitrous acid degraded heparin with aldehyde groups (prepared essentiallyas in Example 2 of U.S. Pat. No. 4,613,665) (5.00 g, 1.0 mmol),cysteamine hydrochloride (0.57 g, 5.0 mmol) and sodium chloride (0.6 g)were dissolved in purified water. The pH was adjusted to 6.0 with 1 MNaOH (aq) and 1 M HCl (aq). To the solution was added 3.1 ml of 5% (aq)NaCNBH₃ (0.16 g, 2.5 mmol) and the reaction was stirred over night atroom temperature. The pH was adjusted to 11.0 with 1 M NaOH (aq) and theresulting product was dialyzed against purified water with a SpectraPordialysis membrane mwco 1 kD (flat width 45 mm) for three days. Thereaction mixture was then concentrated and freeze dried to obtain 2.6 gof a white fluffy powder.

EXAMPLE 3b Preparation of Alkyne Functionalized Nitrous Acid DegradedHeparin

Reagents:

-   -   (i) Nitrous acid degraded heparin with aldehyde groups (prepared        essentially as in Example 2 of U.S. Pat. No. 4,613,665) 3.25 g        dry weight (0.65 mmol)    -   (ii) O-(prop-2-ynyl)-hydroxylamine hydrochloride (Ref: Xu, R.;        Sim, M. K.; Go, M. L., Synthesis and pharmacological        characterization of O-alkynyloximes of tropinone and        N-methylpiperidinone as muscarinic agonists. J Med Chem 1998,        41, (17), 3220-3231) 0.70 g dry weight (6.5 mmol)    -   (iii) Acetic acid (100% Merck) 3 mL    -   (iv) Purified water 50 mL

The compounds were dissolved in the mixed solvents and the pH adjustedto 4.5 with 4M NaOH.

The reaction was continued for 3 days at room temperature. The resultingproduct was dialyzed against purified water with a SpectraPor dialysismembrane mwco 1 kD (flat width 45 mm).

The functionalized product was analyzed by FTIR which showed a typicalsignal from the alkyne at 3100 cm⁻¹.

The activity of the functionalized heparin was 96 IU/mg which indicatesthat the activity of the functionalized heparin is substantiallyunaffected by functionalization.

EXAMPLE 3c Preparation of Alkyne Functionalized Native Heparin

The native heparin (SPL, Scientific Protein Laboratories, lot no. 1037)was functionalized according to the procedures described in Example 3b.

The activity of the functionalized heparin was 211 IU/mg which indicatesthat the activity of the functionalized heparin is substantiallyunaffected by functionalization.

EXAMPLE 3d Preparation of Alkyne Functionalized Native Heparin withAromatic Spacer

The native heparin (SPL, Scientific Protein Laboratories, lot no. 1037)(20 mg) was dissolved in 250 μL acetic acid (100% Merck) and 250 μLpurified water and 6 μL N-(4-(2-(aminoxy)ethyl)phenyl)pent-4-ynamidefrom stock solution (see Example 5 below) was added. The reaction wascarried out at room temperature for 16 hrs. The reaction products wereconcentrated and co-evaporated with toluene (3×2 mL) to give a yellowishsolid (˜20 mg).

Preparation of Intermediates EXAMPLE 5 Bifunctional Linker

5 a) N-(4-(2-(hydroxy)ethyl)phenyl)pent-4-ynamide

N-hydroxysuccinimide-(4-pentynoate) (Ref: Malkoch, M.; Schleicher, K.;Drockenmuller, E.; Hawker, C. J.; Russell, T. P.; Wu, P.; Fokin, V. V.,Structurally Diverse Dendritic Libraries: A Highly EfficientFunctionalization Approach Using Click Chemistry. Macromolecules 2005,38, (9), 3663-3678.) (200 mg, 1.0 mmol) and p-aminophenylethanol (125mg, 0.9 mmol) were dissolved in 2 mL of dichloromethane together withtriethyl amine (140 μL, 1.0 mmol), and 5 drops of dimethyl formamide.The reaction mixture was stirred at room temperature for 2 hours. Thecrude reaction product was concentrated, dissolved in 10 mL of ethylacetate and washed with 5 mL of water followed by, 5 mL of 0.5 M HCl(aq.), 5 mL of 10 NaHCO₃ (aq.) and finally 5 mL of water. The organicphase was dried with MgSO₄, filtered, and the solvent was evaporated.The product was further purified by column chromatography on silica geleluting with a gradient of toluene (T) and ethyl acetate (E) from 4:1 to1:2 (T:E). The product N-(4-(2-(hydroxy)ethyl)phenyl)pent-4-ynamide wascharacterized by NMR and MALDI-TOF.

5 b) N-(4-(2-(methanesulfonate)ethyl)phenyl)pent-4-ynamide

N-(4-(2-(hydroxy)ethyl)phenyl)pent-4-ynamide (210 mg, 1.0 mmol) wasdissolved in 4 mL of pyridine. Methanesulfonyl chloride (MsCl) (100 μL,1.3 mmol) was added at 0° C. The stirred reaction was brought back toroom temperature and reacted at room temperature for 5 min. The solventwas evaporated and the residue re-dissolved in 10 mL of ethyl acetateand washed with 5 mL of water followed by 5 mL of 0.1 M HCl (aq.), andfinally 5 mL of water. The organic phase was dried with MgSO₄, filtered,and the solvent was evaporated to yield the productN-(4-(2-(methanesulfonate)ethyl)phenyl)pent-4-ynamide.

5 c) N-(4-(2-(N-oxyphthalimide)ethyl)phenyl)pent-4-ynamide

The N-(4-(2-(methanesulfonate)ethyl)phenyl)pent-4-ynamide was dissolvedin 6 mL of acetonitrile and added to a solution of N-hydroxyphthalimide(200 mg, 0.9 mmol) and triethyl amine (250 μl, 1.8 mmol) in 2 mLacetonitrile. The reaction mixture was stirred at 50° C. for 2 days. Thereaction mixture was then diluted with 40 mL of ethyl acetate and washedwith 20 mL of 0.5 M HCl (aq.), 5×30 mL of 10 NaHCO₃ (aq.) to remove thered color, and finally 5 mL of water. The organic phase was dried withMgSO₄, filtered, and the solvent was evaporated. The crude product wasre-crystallized from 10 mL of toluene to obtainN-(4-(2-(N-oxyphthalimide)ethyl)phenyl)pent-4-ynamide which wascharacterized by NMR and MALDI-TOF.

5 d) N-(4-(2-(aminoxy)ethyl)phenyl)pent-4-ynamide

N-(4-(2-(N-oxyphthalimide)ethyl)phenyl)pent-4-ynamide (20 mg, 5.5 μmol)and ethylenediamine (200 μL, 3.0 mmol) was dissolved in 2 mL of ethanol.The reaction was stirred at 75° C. for 2 hours. The solvent wasevaporated and the crude product purified by column chromatography onsilica gel eluting with a gradient of toluene (T) and ethyl acetate (E)from 2:1 to 1:3 (T:E). The productN-(4-(2-(aminoxy)ethyl)phenyl)pent-4-ynamide was characterized by NMRand MALDI-TOF.

Preparation of Stock Solution:

N-(4-(2-(aminoxy)ethyl)phenyl)pent-4-ynamide (2.5 mg) was placed in ametric flask and acetonitrile (1000 μL) was added to dissolve thelinker.

Throughout the specification and the claims which follow, unless thecontext requires otherwise, the word ‘comprise’, and variations such as‘comprises’ and ‘comprising’, will be understood to imply the inclusionof a stated integer, step, group of integers or group of steps but notto the exclusion of any other integer, step, group of integers or groupof steps.

All patents and patent applications mentioned throughout thespecification of the present invention are herein incorporated in theirentirety by reference.

The invention embraces all combinations of preferred and more preferredgroups and suitable and more suitable groups and embodiments of groupsrecited above.

The invention claimed is:
 1. A process for the production of a solidobject having a surface which comprises an outer coating layer, saidouter coating layer being a biocompatible composition comprising apolymer and an anti-coagulant entity capable of interacting withmammalian blood to prevent coagulation or thrombus formation, whichanti-coagulant entity is covalently attached to said polymer through alinker comprising a thioether; which process comprises the reaction of acorresponding anti-coagulant entity carrying an alkene or alkyne groupwith a corresponding surface carrying a thiol group, or the reaction ofa corresponding anti-coagulant entity carrying a thiol group with acorresponding surface carrying an alkene or alkyne group.
 2. A processaccording to claim 1 comprising: (a) treating a solid object to presenta surface comprising a cationic polymer outer coating layer which hasbeen functionalized to bear thiol groups; (b) reacting said cationicpolymer outer coating layer which has been functionalized to bear thiolgroups with an anti-coagulant entity which is functionalized to bear analkene or alkyne group; thereby to attach the anti-coagulant entity tothe cationic polymer through a linker comprising a thioether.
 3. Aprocess according to claim 1 comprising: (a) treating a solid object topresent a cationic polymer outer coating layer which has beenfunctionalized to bear alkene or alkyne groups; (b) reacting saidcationic polymer outer coating layer which has been functionalized tobear alkene or alkyne groups with an anti-coagulant entity which isfunctionalized to bear a thiol group; thereby to attach theanti-coagulant entity to the cationic polymer through a linkercomprising a thioether.
 4. A process according to claim 1 comprising:(a) treating a solid object to present a cationic polymer surface layer;(b) associating with said cationic polymer surface layer afunctionalized cationic polymer bearing a multiplicity of negativelycharged anti-coagulant entities which are attached thereto via a linkercomprising a thioether, said cationic polymer bearing a multiplicity ofnegatively charged anti-coagulant entities and said functionalizedcationic polymer having a net negative charge.
 5. A process according toclaim 1 comprising: (a) treating a solid object to present an anionicpolymer surface layer; (b) associating with said anionic polymer surfacelayer a functionalized cationic polymer bearing a multiplicity ofnegatively charged anti-coagulant entities which are attached theretovia a linker comprising a thioether, said functionalized cationicpolymer bearing a multiplicity of negatively charged anti-coagulantentities and having a net positive charge.
 6. A process according toclaim 5, wherein the anionic polymer is dextran sulfate or a derivativethereof.
 7. A process according to claim 2, wherein the cationic polymeris a polyamine.
 8. A process according to claim 1, wherein the solidobject is a medical device.
 9. A process according to claim 1, whereinthe solid object has a surface which comprises one or more layers ofpolysaccharide and polyamine, which process comprises the reaction of acorresponding surface having an outer layer of polysaccharide which hasa net negative charge with a polyamine, carrying a correspondinganti-coagulant entity through a linker comprising a thioether, having anet positive charge.
 10. A process according to claim 1, wherein thesolid object has a surface which comprises one or more layers ofpolysaccharide and polyamine, which process comprises the reaction of acorresponding surface having an outer layer of polysaccharide which hasa net negative charge with a polyamine carrying an thiol or an alkene oralkyne group which has a net positive charge and reacting the resultingproduct with an anti-coagulant entity carrying an alkene or alkyne or athiol group respectively.
 11. A process according to claim 1, whereinthe solid object has a surface which comprises one or more layers ofpolysaccharide and polyamine, which process comprises the reaction of acorresponding surface having an outer layer of polyamine having a netpositive charge with a polyamine carrying a multiplicity ofcorresponding anti-coagulant entities through a linker comprising athioether such that said polyamine has a net negative charge.
 12. Aprocess according to claim 4 wherein the negatively chargedanti-coagulant entities are heparin moieties.
 13. A process according toclaim 5 wherein the negatively charged anti-coagulant entities areheparin moieties.